netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

 Details...
08.03.04.02  Expand sub section  Prostate cancer and gonadorelin analogues
08.03.04.02  Expand sub section  Gonadorelin analogues
08.03.04.02  Expand sub section  Anti-androgens
Bicalutamide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Bicalutamide 50mg tablets
Bicalutamide 150mg tablets

 
   
Cyproterone acetate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Cyproterone acetate 50mg tablets
Cyproterone acetate 100mg tablets

 
   
Flutamide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Flutamide 250mg tablets

 
   
Abiraterone acetate
(Zytiga)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Zytiga®(abiterone acetate) 500mg tablets

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Link  NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
   
Enzalutamide (Xtandi)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Link  NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary